Catherine Hoofd

Catherine Hoofd is an experienced Director and head of Preclinical R&D at iTeos Therapeutics, a position held since January 2016, with previous roles as Associate Director - Project Lead, Head of Tumor Immunology & Target Validation, Principal Scientist, Senior Scientist, and Scientist. Prior to this, Catherine served as a Postdoctoral Fellow at the Terry Fox Laboratory associated with BC Cancer Agency from August 2012 to January 2016, focusing on research related to Chronic Lymphocytic Leukemia (CLL) pathogenesis. Catherine earned a Doctorate in Sciences agronomiques et ingénierie biologique from Université libre de Bruxelles and a degree in Ingénieur chimiste et des bioindustries, specializing in Biotechnology from the same institution. Current projects include defining the role of NOTCH1 in CLL.